Best Peptides for Injury Recovery: Evidence-Based Rankings
Why Peptides Stand Out for Injury Recovery
When it comes to accelerating healing from injuries, peptides represent a fundamentally different approach than conventional supplements. Unlike vitamins, minerals, or amino acid blends that provide general nutritional support, peptides are short chains of amino acids that directly signal your body's repair mechanisms at a molecular level.
Conventional supplements work passively—they provide building blocks your body may or may not use efficiently. Peptides work actively—they bind to specific receptors and trigger targeted biological cascades that enhance bone formation, nerve regeneration, tissue repair, and inflammation management. This is why the clinical evidence for peptides in injury recovery is so compelling: they're not just supporting healing; they're orchestrating it.
The research behind the peptides below comes from randomized controlled trials (RCTs), meta-analyses, and large animal studies—the gold standard of evidence. Each peptide has demonstrated measurable improvements in concrete outcomes: faster fracture healing times, improved neurological recovery, enhanced nerve fiber regeneration, and better functional outcomes in real patients.
This article ranks the most effective peptides for injury recovery based on the strength of evidence supporting their use, with specific data on efficacy, dosing, cost, and practical application.
1. Teriparatide (Forteo) — Tier 4 Evidence
What It Is
Teriparatide is a recombinant parathyroid hormone (PTH 1-34) that's FDA-approved for osteoporosis. While approved for bone density, its off-label application for accelerating fracture healing is supported by the highest level of clinical evidence available.
Evidence Tier & Key Findings
Teriparatide is the only peptide on this list with Tier 4 evidence—the gold standard. Multiple randomized controlled trials and meta-analyses confirm its efficacy for fracture healing.
A meta-analysis of osteoporotic fracture patients found that teriparatide reduced radiological fracture healing time by 4.54 days overall (95% CI –8.80 to –0.28). For lower limb fractures specifically—the most clinically important category—the reduction was even more dramatic: 6.24 days faster across five RCTs involving 251 patients.
In atypical femoral fractures, where healing is notoriously difficult, teriparatide showed even stronger effects. It increased early bone union rates (RR=1.45, 95% CI [1.13, 1.87], p=0.004) and reduced time to union by 1.56 months (p=0.02) across six studies with 214 patients.
Dosing & Cost
- Dosing: 20 mcg once daily via subcutaneous injection
- Cost: $800–$3,200 per month
- Treatment Duration: Typically 6–12 months for fracture healing applications
Who It's Best For
- Patients with complex or non-union fractures
- Older adults (osteoporotic populations) with hip, spine, or femoral fractures
- Athletes with significant bone injuries where accelerated healing provides competitive advantage
- Anyone where conventional healing timelines are medically or professionally unacceptable
Important Note: Teriparatide carries a black box warning for osteosarcoma risk in animal studies, though human epidemiological data hasn't confirmed this. It's typically reserved for serious fractures where the benefit-risk calculation favors its use.
2. SS-31 (Elamipretide) — Tier 3 Evidence
What It Is
SS-31, branded as elamipretide, is a mitochondrial-targeting peptide that protects cells from damage during ischemia-reperfusion injury—the kind of oxidative stress that occurs when blood flow is disrupted and then restored, as happens in severe injuries, surgery, and organ transplants.
Evidence Tier & Key Findings
SS-31 has Tier 3 evidence from two small human RCTs demonstrating improvements in tissue protection during injury, supported by extensive mechanistic evidence from animal models. The human evidence is limited but directionally consistent.
In a Phase 2a RCT of renovascular hypertension patients (n=14), elamipretide produced striking results: patients given the peptide showed post-operative hypoxia reduction to -6% compared to +47% in placebo (P<0.05). The treatment group also showed 30% increased renal blood flow (262±115 mL/min at 3 months) compared to controls.
Animal models in dogs with heart failure showed similar protection: ejection fraction improved from 30±2% to 36±2% (P<0.05), and NT-proBNP (a marker of cardiac stress) decreased by 774±85 pg/mL versus increasing by 88±120 pg/mL in controls.
Dosing & Cost
- Dosing: 0.1–0.5 mg/kg body weight, or fixed 4–40 mg once daily via subcutaneous or intravenous injection
- Cost: $80–$400 per month
- Treatment Duration: Typically 4–12 weeks for acute injury
Who It's Best For
- Patients recovering from major surgery with high ischemia-reperfusion risk
- Those with vascular injuries or compromised blood flow to injury sites
- Individuals with injuries affecting organ systems (kidney, heart, muscle)
- Anyone seeking to minimize oxidative damage during the acute recovery phase
3. LL-37 (Cathelicidin) — Tier 3 Evidence
What It Is
LL-37 is an antimicrobial peptide naturally produced by your immune cells. Beyond its infection-fighting role, LL-37 directly stimulates wound healing, tissue repair, and angiogenesis (new blood vessel formation)—all critical for injury recovery.
Evidence Tier & Key Findings
LL-37 has Tier 3 evidence from one human RCT in wound healing and consistent mechanistic data. The clinical evidence is robust within its specific application domain.
In a randomized trial testing LL-37 cream on diabetic foot ulcers, the peptide significantly increased the granulation index (a measure of healthy tissue formation) compared to placebo on days 7, 14, 21, and 28 (p=0.031, 0.009, 0.006, 0.037 respectively).
Expression studies in human gingival tissue showed that LL-37 gene expression increased 4.3–5.1 fold at one month post-treatment (n=30, p<0.001), demonstrating sustained biological activity.
Dosing & Cost
- Dosing: 100–500 mcg once daily via injection or topical application
- Cost: $40–$180 per month
- Treatment Duration: 4–12 weeks for acute injuries; can be used longer for chronic wounds
Who It's Best For
- Patients with slow-healing wounds or ulcers
- Those with diabetic or vascular complications affecting healing
- Individuals seeking to prevent infection while accelerating tissue repair
- Anyone with acute lacerations or soft tissue injuries
4. ARA-290 (Cibinetide) — Tier 3 Evidence
What It Is
ARA-290 is a non-erythropoietic erythropoietin analog—a peptide that activates tissue protection pathways without stimulating red blood cell production. It's particularly effective for nerve fiber regeneration and neuroprotection.
Evidence Tier & Key Findings
ARA-290 has Tier 3 evidence from three human RCTs showing improvements in nerve regeneration and functional recovery. Sample sizes are modest (n=28–64) and treatment periods are short, but results are consistent.
In a Type 2 diabetes study (n=64), patients receiving 4 mg ARA-290 daily for 28 days showed significantly increased corneal nerve fiber density compared to placebo, particularly in patients with baseline nerve loss. Neuropathic pain improved meaningfully on standardized questionnaires, with effects persisting 28 days after treatment ended.
In a sarcoidosis study (n=28), 28 days of ARA-290 treatment significantly increased corneal nerve fiber area, regenerated GAP-43+ intraepidermal fibers (markers of active nerve growth), and improved the 6-minute walk test. Patients reported clinically meaningful pain reduction.
Dosing & Cost
- Dosing: 4 mg once daily via subcutaneous injection
- Cost: $180–$480 per month
- Treatment Duration: 28 days with potential repeat courses
Who It's Best For
- Patients with nerve injuries or neuropathic pain
- Those with peripheral nerve damage from trauma or disease
- Individuals seeking nerve regeneration after surgery
- Anyone with small fiber neuropathy affecting healing